Acer Therapeutics Inc. (ACER)
$0.758
Rating:
Recommendation:
Buy
| Symbol | ACER |
|---|---|
| Price | $0.758 |
| Beta | 0.649 |
| Volume Avg. | 0.48M |
| Market Cap | 17.740M |
| Shares () | - |
| 52 Week Range | 0.65-4.56 |
| 1y Target Est | - |
| DCF Unlevered | ACER DCF -> | |
|---|---|---|
| DCF Levered | ACER LDCF -> | |
| ROE | 318.33% | Strong Buy |
| ROA | -327.62% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | -169.35% | Sell |
| P/E | -0.60 | |
| P/B | -0.71 |
Latest ACER news
About
Download (Excel)Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts.